Zobrazeno 1 - 10
of 416
pro vyhledávání: '"A. I. SEMENOVA"'
Autor:
E. A. Degtiareva, S. A. Protsenko, E. N. Imyanitov, G. M. Teletaeva, D. Kh. Latipova, A. I. Semenova, A. V. Novik
Publikováno v:
Сибирский онкологический журнал, Vol 21, Iss 5, Pp 162-167 (2022)
Background. The development of unique immune-related adverse events (irAEs) is a known hallmark of immunotherapy. Generally, such complications occur during the first 3–6 months of immunotherapy, however, the experience with immune checkpoint inhib
Externí odkaz:
https://doaj.org/article/cfda88e2472c45b3aad1f09ca00782ed
Autor:
G. M. Teletaeva, E. A. Ulrikh, D. Kh. Latipova, A. I. Semenova, E. V. Levchenko, D. G. Ulrikh, I. V. Berlev, T. Yu. Semiglazova, S. A. Protsenko, A. F. Urmancheeva
Publikováno v:
Опухоли женской репродуктивной системы, Vol 16, Iss 3, Pp 67-71 (2021)
Gestational trophoblastic disease is a rare tumor highly sensitive to systemic drug therapy. The standard regimens of chemotherapy of I and II lines for patients in the high-risk group for gestational trophoblastic disease are the EMA-CO, EMA-EP and
Externí odkaz:
https://doaj.org/article/60736af458fb4801999c1654f4987569
Autor:
S. A. Protsenko, E. N. Imyanitov, A. I. Semenova, D. Kh. Latipova, A. V. Novik, D. O. Yurlov, A. P. Oganesian
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 54-61 (2020)
Melanoma of the skin is one of the most aggressive malignant neoplasms. Metastatic skin melanoma has an extremely poor clinical prognosis with a high mortality rate, accounting for 80% of all deaths from skin malignancies. The approaches to the treat
Externí odkaz:
https://doaj.org/article/b0018e303c634f01befa2d7bfd783831
Autor:
A. V. Novik, E. V. Yaremenko, E. M. Anokhina, T. L. Nehaeva, A. I. Semenova, D. Kh. Latipova, S. A. Protsenko, I. A. Baldueva
Publikováno v:
Сибирский онкологический журнал, Vol 18, Iss 4, Pp 13-20 (2019)
Special systems were developed for response assessment of immunooncology drugs. The role and benefits of particular system in assessing the efficacy of different immunotherapy methods are not clear yet. The objective of this study is to compare the r
Externí odkaz:
https://doaj.org/article/3183b6a271c74be9968e3a390a3f99a9
Autor:
Z. S. Kotova, T. Yu. Semiglazova, I. A. Baldueva, D. H. Latipova, D. O. Yurlov, V. V. Semiglazov, G. M. Teletaeva, A. V. Novik, A. I. Semenova, S. A. Protsenko
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 172-175 (2018)
The aim of this study is to analyse the efficacy of efferent therapy (hemosorption) as part of drug treatment in patients with metastatic colorectal cancer (mCRC) based on the use of standard first-line chemotherapy combined with the bevacizumab bios
Externí odkaz:
https://doaj.org/article/4b8d8806db7444a88919e0781d762df9
Autor:
T. Y. SEMIGLAZOVA, V. A. KLYUGE, E. A. KOROBEYNIKOVA, P. V. KRIVOROTKO, R. M. PALTUEV, G. M. TELETAEVA, D. H. LATIPOVA, V. V. KLIMENKO, E. V. TACHENKO, A. V. Novik, A. I. SEMENOVA, V. V. SEMIGLAZOV, S. A. PROTSENKO, V. F. SEMIGLAZOV
Publikováno v:
Медицинский совет, Vol 0, Iss 6, Pp 72-83 (2017)
The review considers information about the efficacy and safety of Ixabepilone as a monotherapy and as a component of combination therapy for advanced breast cancer. Successful treatment of metastatic breast cancer is often confounded by resistance to
Externí odkaz:
https://doaj.org/article/a411c9ac77e14e4eb0bc624119f30783
Autor:
T. Y. SEMIGLAZOVA, A. S. ZHABINA, А. V. BELYAEVA, V. A. KLUGE, K. V. USOVA, D. H. LATIPOVA, G. M. TELETAEVA, A. V. NOVIK, A. I. SEMENOVA, S. A. PROTSENKO
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 56-65 (2016)
Conversion of the incurable disease in the chronic form and improvement of the life quality parameters on the background of appearance of new drugs is of specific importance for patients with NSCLC with activating mutations. “ESMO thinks that treat
Externí odkaz:
https://doaj.org/article/7ac0b7e66bad4bcaa3c872a3ba8a7d62
Autor:
G. M. TELETAEVA, T. Y. SEMIGLAZOVA, А. S. ZHABINA, D. H. LATIPOVA, V. V. KLIMENKO, Z. S. KOTOVA, A. I. SEMENOVA, S. A. PROTSENKO, V. V. SEMIGLAZOV
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 74-83 (2016)
Modern therapeutic approaches allow achieving stable therapeutic effect, extension and maximum long-term preservation of the quality of life of metastatic mammary gland cancer patients. Currently there is no optimal consequence of cytostatic agents u
Externí odkaz:
https://doaj.org/article/89d181bcd2e64ba48715dabe1c38087a
Autor:
Konstantin K. Laktionov, Elena V. Artamonova, Tatiana N. Borisova, Valeriy V. Breder, Iurii M. Bychkov, Liubov Iu. Vladimirova, Nikita M. Volkov, Stepan M. Ergnian, Albina S. Zhabina, Pavel V. Kononets, Alexander E. Kuzminov, Evgeny V. Levchenko, Olga A. Malikhova, Dimitr T. Marinov, Sergey V. Miller, Fedor V. Moiseenko, Valeriia V. Mochal’nikova, Sergei N. Novikov, Oleg V. Pikin, Elena V. Reutova, Evgenii O. Rodionov, Dina D. Sakaeva, Ksenia A. Sarantseva, Anna I. Semenova, Aleksei V. Smolin, Vladimir M. Sotnikov, Sergei A. Tuzikov, Igor N. Turkin, Igor E. Tyurin, Vladimir D. Chkhikvadze, Konstantin I. Kolbanov, Marina V. Chernykh, Andrei V. Chernichenko, Aleksandr A. Fedenko, Elena V. Filonenko, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, Tigran G. Gevorkian, Aleksei V. Butenko, Ilmira R. Gil’mutdinova, Irina V. Gridneva, Mikhail A. Eremushkin, Margarita A. Zernova, Boris S. Kasparov, Denis V. Kovlen, Kristina O. Kondrat’eva, Tatiana V. Konchugova, Svetlana B. Korotkova, Anton A. Krutov, Olga A. Obukhova, Gennadii N. Ponomarenko, Tatiana Iu. Semiglazova, Aleksandra M. Stepanova, Marina M. Khulamkhanova
Publikováno v:
Современная онкология, Vol 24, Iss 3, Pp 269-304 (2022)
Externí odkaz:
https://doaj.org/article/a2caace9aacc43548d9d996d4c2021f2
Publikováno v:
Медицинский вестник Юга России, Vol 13, Iss 1, Pp 117-123 (2022)
Purpose: to study the functional parameters of the innate immune response in various clinical courses of seasonal allergic rhinitis.Materials and methods: a comparative prospective study was conducted. 62 participants (patients with seasonal allergic
Externí odkaz:
https://doaj.org/article/28d93a0a4d5e4836acb4b3461de3c122